Brand Name

Rexulti

Generic Name
Brexpiprazole
View Brand Information
FDA approval date: July 10, 2015
Classification: Atypical Antipsychotic
Form: Tablet, Kit

What is Rexulti (Brexpiprazole)?

REXULTI is indicated for: Adjunctive treatment to antidepressants for major depressive disorder in adults Treatment of schizophrenia in adults and pediatric patients ages 13 years and older Treatment of agitation associated with dementia due to Alzheimer's disease Limitations of Use: REXULTI is not indicated as an as needed treatment for agitation associated with dementia due to Alzheimer's disease [see Clinical Studies (1.
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

Summary: This is a study that will test a predictive biomarker algorithm based on results from a previous study. The goal of this study is to integrate clinical, imaging, EEG, and molecular data across 8 sites to predict treatment outcome for patients experiencing a major depressive episode (MDE).

A Phase I Clinical Study of the Safety, Tolerability, and Pharmacokinetics of a Single Dose of Brexpiprazole Long-acting Injection in Healthy Subjects/Patients With Schizophrenia.

Summary: Study to evaluate the safety and tolerability of single ascending doses of brexpiprazole long-acting injection in healthy subjects/patients with schizophrenia.

A Pharmacogenetic Human Laboratory Investigation of Brexpiprazole in Alcohol Use Disorder

Summary: Few medications are currently Food \& Drug Administration (FDA)-approved for the treatment of Alcohol Use Disorder (AUD), and those that are have, on average, modest effects on drinking. Precision medicine research has explored whether patient-level variables, such as genetic variation, may identify subgroups of individuals with larger medication effects, but few findings have been replicated. A p...